PHARMACOECONOMIC APPROACHES FOR PHARMACOTHERAPY OF RHEUMATOID ARTHRITIS

Introduction. With the spread of the coronavirus pandemic, the role of pharmacotherapy of rheumatoid arthritis (RA) among patients with dual health disorders and in patients with systemic diseases is growing. This article is devoted to pharmacoeconomic for the pharmacotherapy of RA based on ABC/VEN analysis. Materials and methods. International and national medical and technological documents on standardization of medical care of RA, as well as scientific sources were used for regulatory, documentary and pharmacoeconomic analysis. ABC analysis was performed as a tool to study the cost of purchasing drugs. VEN analysis was performed to classify drugs into categories V, E and N on the principles of evidence-based medicine, forensic pharmacy, evidence-based pharmacy. Results. On the first stage of the research was conducted clinical and pharmacological analysis, the next stages - marketing and pharmacoeconomic analysis. Based on the ABC/VEN analysis, a matrix of the consolidated ABC/VEN analysis was developed. Discussion. The largest share (66.7 %) falls on the ATC classification code L "Antineoplastic and immunomodulatory agents". According to the results of marketing analysis tablets occupy 50 % of doctors' appointments; 75 % of the studied drugs have an unlimited validity of registration certificates. Ranking of country of origin of manufacturers of studied drugs: Germany – 37.6 %. Category A included five drugs’ INN (Mycophenolic acid, Azathioprine, Cyclophosphamide, Methotrexate, Ciclosporine), the cost of one dose is 5241.1 UAH, which is 78.12 % of the total cost of treatment for a patient with RA. It was found that six drugs INN (Methotrexate, Sulfasalazine, Hydroxychloroquine, Azathioprine, Ciclosporine, Cyclophosphamide) belong to category V (Vital). Conclusion. The introduction of information about pharmacoeconomic for pharmacotherapy of RA in the activities of health care institutions will ensure proper organization of the order of drug circulation at the stages of prescribing, prescribing, storage, accounting, quality control, transportation, release, destruction, licensing in accordance with current medical and pharmaceutical legislation.

Download Full-text

An evidence-based medicine approach to economic studies: assessing the cost-effectiveness of competing strategies for colorectal cancer screening

Clinical Gastroenterology and Hepatology ◽

10.1053/s1542-3565(03)00181-2 ◽

2003 ◽

Vol 1 (5) ◽

pp. 404-413 ◽

Cited By ~ 3

Author(s):

John M Inadomi ◽

Amnon Sonnenberg

Keyword(s):

Colorectal Cancer ◽

Cost Effectiveness ◽

Cancer Screening ◽

Colorectal Cancer Screening ◽

Evidence Based Medicine ◽

Evidence Based ◽

The Cost ◽

Based Medicine ◽

Economic Studies

Download Full-text

The usage of pharmaceutical drugs in dentistry

SUCHASNA STOMATOLOHIYA ◽

10.33295/1992-576x-2020-3-24 ◽

2020 ◽

Vol 102 (3) ◽

pp. 24

Author(s):

I. Mazur ◽

◽

D. Stavska ◽

L. Gelashvili ◽

◽

...

Keyword(s):

Postgraduate Education ◽

New Drugs ◽

Evidence Based ◽

Pharmaceutical Drugs ◽

National Medical ◽

Medical Academy ◽

Survey Results ◽

Inflammatory Drugs ◽

Local Use ◽

Based Medicine

The analysis of the most frequently recommended medications is showed in the article. The results of the survey of dentists conducted at the Shupyk National Medical Academy of Postgraduate Education in collaboration with Ukrainian Dental Association on dental conferences in February-March 2015. The basic group of pharmaceutical drugs – nonsteroidal anti-inflammatory drugs, antibiotics, and medicines for local use were researched. The analysis presents the most commonly prescribed drugs by dentists during the period of first half-year 2015. The survey results demonstrated the necessity to better inform dentists about new drugs and their indications for the usage based on evidence-based medicine, contraindications, and side effects in order to achieve high clinical efficacy of the treatment.

Download Full-text

Flawed Approaches to Determining the “Most Accurate Impairment Rating”: The California Experience

Guides Newsletter ◽

10.1001/amaguidesnewsletters.2017.julaug01 ◽

2017 ◽

Vol 22 (4) ◽

pp. 3-5

Author(s):

Christopher R. Brigham ◽

James B. Talmage ◽

Marjorie Eskay-Auerbach

Keyword(s):

Best Interests ◽

Injured Workers ◽

Personal Injury ◽

Evidence Based ◽

Validity And Reliability ◽

Permanent Disability ◽

Sixth Edition ◽

Financial Interest ◽

The Cost ◽

Based Medicine

Abstract Socioeconomic factors influence all aspects of workers’ compensation, personal injury, and disability systems, but the best financial interest of certain stakeholders may not be aligned with the ultimate best interests of those who are injured or ill. The AMA Guides to the Evaluation of Permanent Impairment (AMA Guides), Fifth Edition, was introduced in California in 2005 to improve the reliability of permanent disability award ratings, which previously were based primarily on subjective factors. The result was a reduction in the dollar value of disability rewards, and, in response, certain stakeholders took steps to reduce this impact, including instructing physicians to ignore instructions in the AMA Guides. The AMA Guides, Sixth Edition, addresses many of the potential misapplications of the criteria in the fifth edition. Despite efforts to improve the validity and reliability of impairment assessment, some stakeholders continue to resist use of the more current edition. In California, impairment currently is rated by agreed medical evaluators; this should be changed to ensure that evaluations are performed by unbiased physicians who are educated with respect to evidence-based medicine and causation. Injured workers must be fairly and appropriately compensated for losses associated with an injury, but not at the cost of inappropriate inflation of impairment and disability ratings because the latter contribute to needless disability and impede living a productive and joyous life.

Download Full-text

Evidence-based Recommendations for the Management of Comorbidities in Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis: Expert Opinion of the Canadian Dermatology-Rheumatology Comorbidity Initiative

The Journal of Rheumatology ◽

10.3899/jrheum.141112 ◽

2015 ◽

Vol 42 (10) ◽

pp. 1767-1780 ◽

Cited By ~ 71

Author(s):

Camille Roubille ◽

Vincent Richer ◽

Tara Starnino ◽

Collette McCourt ◽

Alexandra McFarlane ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Clinical Practice ◽

Psoriatic Arthritis ◽

Potential Effect ◽

Cochrane Library ◽

Evidence Based ◽

Grade Of Recommendation ◽

The Cochrane Library ◽

Based Medicine ◽

Level Of Agreement

Objective.Comorbidities such as cardiovascular diseases (CVD), cancer, osteoporosis, and depression are often underrecognized in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), or psoriasis (PsO). Recommendations may improve identification and treatment of comorbidities. The Canadian Dermatology-Rheumatology Comorbidity Initiative reviewed the literature to develop practical evidence-based recommendations for management of comorbidities in patients with RA, PsA, and PsO.Methods.Eight main topics regarding comorbidities in RA, PsA, and PsO were developed. MEDLINE, EMBASE, and the Cochrane Library (1960–12/2012), together with abstracts from major rheumatology and dermatology congresses (2010–2012), were searched for relevant publications. Selected articles were analyzed and metaanalyses performed whenever possible. A meeting including rheumatologists, dermatologists, trainees/fellows, and invited experts was held to develop consensus-based recommendations using a Delphi process with prespecified cutoff agreement. Level of agreement was measured using a 10-point Likert scale (1 = no agreement, 10 = full agreement) and the potential effect of recommendations on daily clinical practice was considered. Grade of recommendation (ranging from A to D) was determined according to the Oxford Centre for Evidence-Based Medicine evidence levels.Results.A total of 17,575 articles were identified, of which 407 were reviewed. Recommendations were synthesized into 19 final recommendations ranging mainly from grade C to D, and relating to a large spectrum of comorbidities observed in clinical practice: CVD, obesity, osteoporosis, depression, infections, and cancer. Level of agreement ranged from 80.9% to 95.8%.Conclusion.These practical evidence-based recommendations can guide management of comorbidities in patients with RA, PsA, and PsO and optimize outcomes.

Download Full-text